NCT02732184 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

Co-ArgI-PEG modified human arginase I

Trial Locations (10)

Vanderbilt-Ingram Cancer Center, Nashville

University Hospitals Case Medical Center, Cleveland

The Cleveland Clinic, Cleveland

Comprehensive Cancer Center at University of Michigan, Ann Arbor

Washington University Medical School, St Louis

Baylor Scott & White, Dallas

University of Texas Southwestern Medical Center, Dallas

University of Alberta, Edmonton

Princess Margaret Cancer Centre, Toronto

Jewish General Hospital, Montreal